Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial

Eur Heart J. 2019 May 14;40(19):1568. doi: 10.1093/eurheartj/ehy743.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anticoagulants
  • Hemorrhage
  • Humans
  • Rivaroxaban*
  • Warfarin*

Substances

  • Anticoagulants
  • Warfarin
  • Rivaroxaban